Valuation: Aytu Bioscience Inc

Market Cap 24.78M 21.79M 20.61M 18.69M 35.1M 2.38B 35.3M 247M 95.28M 1.21B 93.02M 91.01M 3.9B P/E 2027 *
-2.65x
P/E 2028 * 6.81x
Enterprise Value 24.78M 21.79M 20.61M 18.69M 35.1M 2.38B 35.3M 247M 95.28M 1.21B 93.02M 91.01M 3.9B EV / Sales 2027 *
0.37x
EV / Sales 2028 * 0.27x
Free-Float
91.84%
Yield 2027 *
-
Yield 2028 * -
Manager TitleAgeSince
Chief Operating Officer 51 2015-04-15
Chief Executive Officer 51 2015-04-15
Director of Finance/CFO 44 2024-11-10
Director TitleAgeSince
Chairman 51 2015-04-15
Director/Board Member 63 2016-04-12
Chairman 59 2024-11-05
Change 5-day change 1-year change 3-year change Capi.($)
-0.15%+14.13%+679.19%+96.84% 79.4B
-4.54%-5.91%+33.93%-10.01% 78.69B
+2.80%+3.60%-6.34%-27.82% 59.52B
-0.89%+2.11%+7.92%+170.43% 46.58B
+2.49%+0.14%-8.95%+33.71% 46.53B
+0.50%+4.12%+64.67%-11.53% 33.63B
+0.68%+0.17%+48.84%+113.04% 25.11B
-3.56%-0.47%+3.11%+135.37% 22.13B
+0.73%-0.95%+57.27%+97.04% 15.31B
Average -0.25%+4.30%+97.74%+66.34% 45.21B
Weighted average by Cap. -0.45%+6.71%+148.74%+53.29%

Financials

2027 *2028 *
Net sales 67.86M 59.69M 56.44M 51.19M 96.14M 6.51B 96.7M 676M 261M 3.32B 255M 249M 10.68B 92.36M 81.23M 76.81M 69.67M 131M 8.87B 132M 920M 355M 4.52B 347M 339M 14.54B
Net income -11.8M -10.38M -9.81M -8.9M -16.72M -1.13B -16.81M -117M -45.38M -578M -44.3M -43.34M -1.86B 4.7M 4.13M 3.91M 3.55M 6.66M 451M 6.7M 46.81M 18.08M 230M 17.65M 17.27M 740M
Net Debt - -
Logo Aytu Bioscience Inc
Aytu BioPharma, Inc. is a pharmaceutical company focused on advancing medicines for complex central nervous system (CNS) diseases. Its business is focused on the launch of EXXUA and its prescription pharmaceutical products sold primarily through third-party wholesalers and pharmacies and which primarily consists of two product portfolios. Its Attention Deficit Hyperactivity Disorder (ADHD) portfolio consists of Adzenys XR-ODT (amphetamine) extended-release orally disintegrating tablets (Adzenys) , Cotempla XR-ODT, and METADATE CD, which are CNS stimulants indicated for the treatment of ADHD in patients. Its Pediatric portfolio consists of Karbinal ER (carbinoxamine maleate extended-release oral suspension), an extended-release first-generation antihistamine indicated to treat various allergic conditions including seasonal and perennial allergic rhinitis, vasomotor rhinitis, Poly-Vi-Flor, and Tri-Vi-Flor. EXXUA is indicated to treat depressive disorder (MDD) in adults.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-